VELOXIS PHARMACEUTICALS AS has a total of 39 patent applications. It decreased the IP activity by 75.0%. Its first patent ever was published in 2002. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, machines and chemical engineering are PHOENIX SCIENT INC, LIFECYCLE PHARMA AS and HOFMANN ROBERT F.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 21 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | Australia | 3 | |
#4 | EAPO (Eurasian Patent Organization) | 2 | |
#5 | Hungary | 2 | |
#6 | Norway | 2 | |
#7 | Japan | 1 | |
#8 | Serbia | 1 | |
#9 | Slovenia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Machines | |
#3 | Chemical engineering |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Unspecified technologies | |
#4 | Unspecified technologies | |
#5 | Chemical or physical processes |
# | Name | Total Patents |
---|---|---|
#1 | Holm Per | 30 |
#2 | Norling Tomas | 16 |
#3 | Skak Nikolaj | 7 |
#4 | Lademann Anne-Marie | 6 |
#5 | Hansen Liselotte | 5 |
#6 | Polvino William J | 4 |
#7 | Gordon Robert D | 4 |
#8 | Norling Thomas | 2 |
#9 | Holm Jannie Egeskov | 2 |
#10 | Slot Lillian | 2 |
Publication | Filing date | Title |
---|---|---|
US2015004154A1 | Regimen for suppressing organ rejection | |
EP2575769A2 | Stabilized tacrolimus composition | |
EP2167033A1 | Once daily oral dosage form comprising tacrolimus | |
EP1663216A1 | Modified release compositions comprising tacrolimus |